Therapeutic Area Coverage KPI

Therapeutic Area Coverage is a vital performance indicator that measures the breadth of a company's product offerings across various medical fields.

This KPI directly influences financial health and operational efficiency by ensuring that resources are allocated effectively to meet market demands.

A well-rounded therapeutic portfolio can enhance strategic alignment with healthcare providers and improve patient outcomes.

Companies that excel in this area often see improved ROI metrics and stronger market positioning.

Tracking this KPI allows executives to make data-driven decisions that can lead to significant business outcomes.

Ultimately, it serves as a benchmark for assessing the effectiveness of product development strategies.

How Therapeutic Area Coverage Connects to Your Strategy

Therapeutic Area Coverage belongs to one KPI group, Biotechnology. That is an industry group rather than a functional one, so it collects in a single set of ninety-five metrics everything a biotech firm runs across research, clinical development, regulatory affairs, manufacturing and commercial operations. Coverage ranks twenty-ninth there. It sits outside the leading tier but inside the same scorecard as the metrics that determine whether breadth is worth having.

The KPI group leads with eight metrics:

• Research & Development Pipeline Strength and Clinical Trial Success Rate, ranked first and second, both in the learning and growth perspective
• Regulatory Approval Success Rate, Time to Market, FDA Inspection Outcomes and Bioproduction Yield, ranked third through sixth, all internal process measures
• Drug Efficacy Improvement Rate in the customer perspective, and New Product Launch Success back in learning and growth

KPI Depot places Therapeutic Area Coverage in the learning and growth perspective, alongside Research & Development Pipeline Strength, Clinical Trial Success Rate and New Product Launch Success. That is the correct home for it and it comes with a warning. Coverage is leading only in the weakest sense. It describes the shape of a portfolio rather than the quality of anyone's work in the period, and a portfolio can be broad and empty.

There is a structural difference between this metric and every metric ranked above it: coverage does not respond to execution. Bioproduction Yield moves when a process engineer changes a step. Time to Market moves when a submission goes in earlier. Coverage moves only when the firm in-licenses, acquires, partners, starts a discovery program or kills one. It is flat for long stretches and then jumps. Charted monthly it produces a staircase that invites stories about momentum where there is only a single decision, and it makes a poor quarterly target for any team that cannot authorize capital allocation.

The real tension in this KPI group is with Clinical Trial Success Rate and Time to Market, the second and fourth ranked metrics. Breadth across therapeutic areas costs a firm the assets that raise both: repeated exposure to the same regulatory reviewers, the same investigator networks, the same endpoints and the same recruitment channels. A firm entering its fifth unrelated area is a first-time filer again, with the approval odds and cycle time of one. Bioproduction Yield creates a second, quieter tension in the same direction, because yield improves with platform concentration and coverage often arrives as a modality the manufacturing organization has never run.

The KPI group points at its own reconciliation. Collaboration and Partnership Index, which appears in the group's OKR material, measures the route by which coverage can be added without spreading internal scientists across unfamiliar biology. Coverage gained through partnership and coverage gained through internal program starts look identical in this ratio and are entirely different bets. If you report the metric, report the route.

Measuring Therapeutic Area Coverage in Practice

The formula is the number of therapeutic areas covered divided by the total addressable therapeutic areas. Both terms are choices rather than facts, and the denominator is not a property of the world that can be looked up.

Taxonomy is the first fork and the one that quietly decides the answer. Disease classification chapters, medical subject heading trees, anatomical therapeutic chemical classes, the commercial classifications used by pharmaceutical market research, and internal franchise labels all produce different counts from the same portfolio. Oncology is one area under a chapter-level scheme and dozens under a tumor-type scheme. A firm can double its reported coverage without touching a single program by moving one level down the tree. The serious version of this error is asymmetry: the numerator gets compiled by hand from program names at fine granularity while the denominator is lifted from a published classification at coarse granularity. The ratio is then not merely imprecise, it is inflated in a predictable direction.

The numerator needs explicit counting rules, decided once and applied to history. Marketed products only, or products plus registration-stage assets, or everything from discovery onward. A discovery-stage molecule with a nominated indication is a very weak claim on an area and it counts the same as a marketed franchise unless you separate stages. Out-licensed and partnered assets need a rule, as do assets acquired and shelved, and programs discontinued but still sitting in the registry because nobody closes records. Label expansion is the subtle one: a single molecule approved across several indications spanning different areas can count once or several times, and firms that count it several times report coverage that no second molecule supports. Geography needs a rule too, since an approval in one region only is real coverage in that region and nothing anywhere else.

No single system holds the inputs. Marketed products live in the regulatory affairs registry, keyed by product and country. Pipeline programs live in portfolio management, keyed by compound or program, with the indication sometimes sitting in a free-text field. Revenue lives in the ERP item master, which knows nothing about indications at all. The join key that would make this clean is indication, and indication lives on the label and in the protocol rather than on the product master. Nearly every implementation therefore ends up with a hand-maintained crosswalk between programs and areas. Date-stamp that crosswalk and keep prior versions, because the most common cause of a jump in this metric is an edit to the crosswalk rather than a change in the portfolio, and without versions you cannot tell the two apart after the fact.

Then there is the word addressable. A cell therapy platform is not addressable across every classified area, and an oral small molecule developer is addressable across a great many. Applying a common denominator to both makes the platform company look narrow when it is simply constrained by its modality. If the denominator is not restricted to areas the firm's modality, capability and capital can plausibly serve, the ratio is measuring the platform rather than the strategy, and it will penalize exactly the specialised firms whose focus is the reason their Clinical Trial Success Rate holds up.

Segment by stage before anything else. Approved coverage, clinical coverage and preclinical coverage are three separate statements about a company, and only the first is a claim on today's revenue. Segment second by ownership, separating wholly owned areas from partnered and in-licensed ones. Then pair breadth with depth, because a single early asset in an area is coverage on paper: report active programs per area or research spend per area beside the ratio. Without that pairing, the metric rewards a scatter of one-program entries, which is the portfolio shape it should be warning you about.

A final note on reading the trend. The ratio is bounded and coarse, so it is insensitive to a lot of real portfolio movement and hypersensitive to denominator revisions. When it changes, establish first whether the numerator moved, the denominator moved, or the crosswalk was edited. Restate the full history whenever the taxonomy changes, and say in the footnote that you did.

Common Pitfalls

Many organizations overlook the importance of regularly assessing their therapeutic area coverage, which can lead to missed opportunities in emerging markets.

• Failing to conduct thorough market research can result in inadequate understanding of customer needs. This oversight often leads to product offerings that do not align with market demand, ultimately affecting sales and profitability.
• Neglecting to update the product portfolio can create gaps in therapeutic coverage. As new diseases emerge and treatment options evolve, outdated offerings can hinder a company's ability to compete effectively.
• Overemphasizing a single therapeutic area may limit overall growth potential. Diversifying across multiple areas is crucial for mitigating risks associated with market fluctuations.
• Ignoring competitor analysis can lead to strategic missteps. Without understanding competitors' strengths and weaknesses, organizations may miss critical insights that inform their own product strategies.

Improvement Levers

Enhancing therapeutic area coverage requires a proactive approach to product development and market engagement.

• Invest in comprehensive market analysis to identify unmet needs. Understanding patient demographics and treatment gaps can guide the development of new products that align with market demand.
• Foster partnerships with healthcare providers to gain insights into emerging therapeutic areas. Collaborating with key stakeholders can inform product development and enhance market relevance.
• Regularly review and update the product portfolio to ensure alignment with current medical trends. This practice helps in maintaining a competitive edge and meeting evolving patient needs.
• Implement a robust feedback mechanism to capture insights from healthcare professionals. Gathering input from end-users can drive innovation and improve therapeutic offerings.

KPI Depot is trusted by consulting, strategy, finance, and analytics teams at leading organizations worldwide, including those listed below.

OKRs That Use Therapeutic Area Coverage

The Biotechnology KPI group publishes three OKR sets. Therapeutic Area Coverage is not written as a key result in any of them, and it should not be forced into one as a growth target, since it moves only on capital allocation decisions. It has two honest roles in the group's existing objectives.

Objective: Accelerate Breakthrough Innovation to Strengthen Our Competitive Pipeline. The key results here are Research & Development Pipeline Strength, Patent Filings, Patent Approval Rate and Collaboration and Partnership Index. Coverage fits as a shape constraint on pipeline growth rather than as a fifth target: grow pipeline strength while adding at most one new therapeutic area, or add a new area only by partnership rather than by an internal program start. Both formulations are directional and event-based, which suits a metric that changes in steps. The group's own guidance on licensing deals as a complementary revenue stream runs the same way, since an area entered through licensing carries different risk, different cost and a different timeline than one entered from a standing start.

Objective: Improve Clinical Trial Execution to Drive Regulatory Success and Speed Approvals. The key results are Clinical Trial Success Rate, Regulatory Approval Success Rate, FDA Inspection Outcomes and Time to Market. Coverage is the counter-metric for this objective: hold it flat for the cycle. A team asked to raise trial success and shorten time to market has one obvious lever, which is to narrow toward indications it already knows. That is frequently the right call. It should be a visible decision by the people who own portfolio strategy rather than a side effect of a quarterly goal, and reporting coverage next to those four key results is what makes the trade visible.

On targets, resist attaching a figure to this KPI in an OKR at all. Any number you could set is a portfolio decision the board has already made or is about to make, not a stretch a team can work toward through effort. Write the key result as the decision itself, to enter an area, to exit one, or to hold, and keep the ratio as the reporting view underneath it.

See OKR Examples for Biotechnology

Free Whitepaper

Want to achieve performance excellence in Biotechnology? Download our in-depth whitepaper: Definitive Guide to Biotechnology KPIs.

Download the Free Guide

KPI Categories

This KPI is associated with the following categories and industries in our KPI database: